Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31703654 | 0.77 | HDAC6 (0.33) | FPR3FPR2ASGR1CA14HDAC1 | |
| SCHEMBL16337389 | 0.75 | CYP4F2 (0.37) | FPR3FPR2ASGR1CA14HDAC1 | |
| SCHEMBL4137259 | 0.75 | PDK2 (0.32) | FPR3FPR2ASGR1HDAC1HDAC2 | |
| SCHEMBL15116573 | 0.75 | CYP4F2 (0.33) | FPR3FPR2ASGR1HDAC1HDAC2 | |
| SCHEMBL23282418 | 0.75 | ASGR1 (0.40) | FPR3FPR2ASGR1HDAC1HDAC2 | |
| SCHEMBL23713791 | 0.74 | P2RX7 (0.30) | — | |
| SCHEMBL22113052 | 0.73 | ASGR1 (0.32) | FPR3FPR2ASGR1HDAC1HDAC2 | |
| SCHEMBL20054494 | 0.73 | FPR3 (0.33) | FPR3FPR2ASGR1HDAC1HDAC2 | |
| SCHEMBL15144523 | 0.72 | HDAC6 (0.37) | ASGR1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL25319106 | 0.72 | CTSL (0.36) | FPR3FPR2ASGR1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | FPR3 179/4885FPR2 168/4885ASGR1 2154/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | FPR3 179/4885FPR2 168/4885ASGR1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.